From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-08
DOI
10.1038/s41571-019-0281-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
- (2019) Giovanni Randon et al. Scientific Reports
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
- (2019) Michiaki Unno et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
- (2019) María Teresa Blasco et al. CANCER CELL
- A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)
- (2019) Dung T. Le et al. CLINICAL CANCER RESEARCH
- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
- (2019) Margaret A. Tempero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
- (2019) M Tempero et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- (2019) Kyle C. Cuneo et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
- (2018) Rajani Kanteti et al. CANCER BIOLOGY & THERAPY
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins
- (2018) Ed S. Kheder et al. CLINICAL CANCER RESEARCH
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
- (2018) Maeve A. Lowery et al. EUROPEAN JOURNAL OF CANCER
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance
- (2018) Marcia Irene Canto et al. GASTROENTEROLOGY
- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
- (2018) Eric Van Cutsem et al. INTERNATIONAL JOURNAL OF CANCER
- HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
- (2018) Sunil R. Hingorani et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.
- (2018) Geertjan Van Tienhoven et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- The IARC Perspective on Colorectal Cancer Screening
- (2018) Béatrice Lauby-Secretan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
- (2018) Andrew J Aguirre et al. Cancer Discovery
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- NRG1 Fusions in KRAS Wild-type Pancreatic Cancer
- (2018) Christoph Heining et al. Cancer Discovery
- Precision Targeted Therapy with BLU-667 for RET -Driven Cancers
- (2018) Vivek Subbiah et al. Cancer Discovery
- Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
- (2018) Deepak Raj et al. GUT
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.
- (2018) Vincent J. Picozzi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- High response rate to PD-1 blockade in desmoplastic melanomas
- (2018) Zeynep Eroglu et al. NATURE
- Molecular Profiling of Pancreatic Cancer Patients—Response
- (2018) Michael J. Pishvaian et al. CLINICAL CANCER RESEARCH
- Optimizing the outcomes of pancreatic cancer surgery
- (2018) Oliver Strobel et al. Nature Reviews Clinical Oncology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
- (2018) Alexander Drilon et al. Cancer Discovery
- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- CAR T-cell therapy for pancreatic cancer
- (2017) Carl J. DeSelm et al. JOURNAL OF SURGICAL ONCOLOGY
- Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
- (2017) Aatur D. Singhi et al. Journal of the National Comprehensive Cancer Network
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
- (2017) Angela Alistar et al. LANCET ONCOLOGY
- Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
- (2017) Sushrut Kamerkar et al. NATURE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma
- (2017) Asma Begum et al. PLoS One
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
- (2017) Mark Yarchoan et al. Oncotarget
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
- (2017) Andrew M. Waters et al. Cold Spring Harbor Perspectives in Medicine
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma
- (2017) Paula Ghaneh et al. ANNALS OF SURGERY
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers
- (2016) Hans Vasen et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
- (2016) Andrew H. Ko et al. PANCREAS
- Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
- (2016) S.-H. Chen et al. Cancer Discovery
- Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma
- (2016) Isabel Poschke et al. OncoImmunology
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer
- (2015) N Hiraoka et al. BRITISH JOURNAL OF CANCER
- Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
- (2015) D. Masso-Valles et al. CANCER RESEARCH
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
- (2015) F. Vena et al. CLINICAL CANCER RESEARCH
- Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
- (2015) Gregory L. Beatty et al. GASTROENTEROLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition
- (2015) Ronan Russell et al. Nature Communications
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
- (2015) A. J. Gunderson et al. Cancer Discovery
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Oncogenic KRAS signalling in pancreatic cancer
- (2014) S Eser et al. BRITISH JOURNAL OF CANCER
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
- (2014) B. M. Wolpin et al. ONCOLOGIST
- Stromal response to Hedgehog signaling restrains pancreatic cancer progression
- (2014) J. J. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM signalling and cancer
- (2013) C A Cremona et al. ONCOGENE
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
- (2013) A. Neesse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
- (2012) J Harder et al. BRITISH JOURNAL OF CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- "Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
- (2010) N. Chan et al. CLINICAL CANCER RESEARCH
- mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
- (2010) Heinz-Josef Klümpen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Effect of Screening Mammography on Breast-Cancer Mortality in Norway
- (2010) Mette Kalager et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Tumor Cell-Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor Growth
- (2009) K. L. Bennewith et al. CANCER RESEARCH
- The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma
- (2008) Mert Erkan et al. Clinical Gastroenterology and Hepatology
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now